Treatment Cost Savings Under PEPFAR Can Be Re-Invested To Increase ARV Reach

In this post in the “Health Affairs Blog,” Matthew Kavanagh, director of U.S. policy and advocacy at Health Global Access Project (GAP), and Marguerite Thorp, a research assistant at Harvard Medical School, examine how HIV/AIDS treatment funding under PEPFAR has “fallen significantly since 2008 in both absolute dollars and as a portion of total budgets — just at a pivotal moment when investment could change the course of the epidemic.” They say that cost-savings due to declining antiretroviral (ARV) drug prices and efficiencies in programs have allowed PEPFAR to continue to scale up the number of people receiving treatment with a shrinking budget, and argue that those cost savings should be re-invested in ARV treatment programs to boost the number of “treatment slots” even higher (11/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.